Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
about
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaSunitinib in solid tumorsEfficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter StudySunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenibChoi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in ItalyManagement of side effects associated with sunitinib therapy for patients with renal cell carcinoma.Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in KoreaEfficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.Targeted therapies in renal cell cancer: recent developments in imagingMetabolism considerations for kinase inhibitors in cancer treatmentSevere clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism.Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysisModifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial.Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.Cardiotoxicity induced by tyrosine kinase inhibitors.Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.Optimizing treatment for metastatic renal cell carcinoma.Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.Examining the relationship between fatigue and cognition after stroke: A systematic review.Sunitinib Possible Sex-Divergent Therapeutic Outcomes.Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule.Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients.Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
P2860
Q26783514-BD6BA86D-D127-41E7-B814-C131ECE3D6EBQ28245467-D5579B00-3768-4F2B-A928-3F12E20DD7B1Q28547506-17B23FB6-A9FB-482D-8991-D369D20C78DBQ33396613-E4D40D9C-E480-4260-9A7B-A53D77C0ACD8Q33410206-17645E72-9C4A-40B9-ACF8-FF70D47CE579Q33613666-649ABE5B-A7DA-4B05-A8CB-1FE7D09AACB2Q33665833-A88DD92E-7E15-4ECF-9A95-E7ECBC9FC4CAQ33708158-A3466CBF-D78A-4695-BF7C-20C171E78812Q33854836-AA77A23D-7348-4BA5-B996-989BAEACB8D6Q33916002-46362975-4308-4CB9-B1E5-D1F1039A75EBQ33931392-9E78BADE-9A69-4D3A-9F7A-061658B19BF0Q34081620-DE3E967D-D41A-4928-8D46-C1A01A141C8FQ34088696-3EC914A7-7C46-46FD-9086-0AEAFF037543Q34134390-94A9AB25-83A1-4E03-85DA-933BAC4F51E1Q35654010-1F099042-6D1A-4A73-93DA-895E3B1E0DC8Q35921573-4B457BD4-1EA5-4250-B99C-A1144293A3A4Q35966757-4FCFCB6E-5FF6-4B9C-A0DD-9DC52987CC04Q36027841-D448692B-40E9-4304-8E1B-989098AF01C8Q36251480-D063D32D-50FC-4CD8-AEA3-1BFC2B09AD63Q36450707-8AF6B83B-F174-4735-8AF3-B6ED56977453Q36746780-953950D8-E787-4B21-9484-965D8A91E81EQ37593059-18689330-DFDE-4F61-91F2-63586DD791C1Q37650644-5513E59C-AA5D-4F51-997B-8D3B33E482BAQ37683755-A40640B1-F84F-4022-A51D-7A8EFFC3BE9DQ37732294-C38FC230-0093-4F4C-B7CD-39965C503C54Q37960915-A4B27AA4-DD0C-4C47-AD2E-F2F2929F0258Q38004605-0C50BB6B-A7E3-4DA1-8F9A-4F84FA748F78Q38176985-7809023C-75F3-4E03-8B95-1438D0B847A9Q38633488-37CF0373-8FA1-4645-938B-263496E56DF3Q38635940-10982480-60F6-4128-90E3-3FC3E284928CQ38703444-1FAC4E28-314B-48C0-A6C3-2A42C1D590CAQ38869600-A82DA7F7-4E14-4360-8888-59766C034124Q39974493-BA7670D5-6579-4B3B-9852-56B2FCE57821Q41269613-BB5F5426-8067-4B20-AF1E-4743200CB7F1Q42593255-ED108712-E50A-4990-8D30-C2508693E292Q45082802-4BBF9AB8-E092-4AC0-8B9B-EC3C46DAFEECQ46627892-C7C1E0D3-096E-45D0-9B3C-652823E7570FQ47108251-7B03887D-FCF7-40D4-AE3B-8F30AB9EBE27Q47123004-BE0500B5-DA77-4CF6-B9F3-B452D47D4EB4Q47618899-4D267F9F-DA97-4959-A0EC-B0C4E3B0DCB1
P2860
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Predictive factors for severe ...... th advanced renal cell cancer.
@en
type
label
Predictive factors for severe ...... th advanced renal cell cancer.
@en
prefLabel
Predictive factors for severe ...... th advanced renal cell cancer.
@en
P2093
P2860
P356
P1476
Predictive factors for severe ...... th advanced renal cell cancer.
@en
P2093
A A M van der Veldt
A J M van den Eertwegh
C N Tillier
H H Helgason
J B A G Haanen
M van Wouwe
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604456
P407
P577
2008-07-01T00:00:00Z